首次无诱因静脉血栓栓塞停抗凝后长期复发风险:系统综述与荟萃分析
该系统综述与荟萃分析纳入18项研究共7515例首次无诱因VTE且已完成至少3个月抗凝治疗的患者,评估停药后复发VTE的速率与累积发生率。停药后第1年复发率每100人年10.3次,2年累积发生率16%,5年25%,10年36%,复发事件致死率4%。
要点
- 首次无诱因VTE停药后第1年复发率每100人年10.3次,10年累积复发率36%。
- 男性10年累积复发率41%高于女性29%,近端DVT或PE合并DVT复发风险高于孤立PE。
- 复发VTE事件致死率为4%,应据此指导长期管理决策与患者预后咨询。
核心结论
- 首次无诱因VTE完成至少3个月抗凝后,复发VTE风险第1年约10%,2年16%,5年25%,10年36%,其中4%的复发事件导致死亡。
研究设计与样本
- 系统综述与荟萃分析,检索Medline、Embase和Cochrane Central Register of Controlled Trials(建库至2019年3月15日)。
- 纳入报告首次无诱因VTE完成至少3个月抗凝停药后症状性复发VTE的随机对照试验和前瞻性队列研究。
- 共纳入18项研究、7515例患者,采用随机效应荟萃分析合并数据。
主要发现
- 停药后复发VTE每100人年速率:第1年10.3次(95%CI 8.6–12.1),第2年6.3次(5.1–7.7),第3–5年3.8次/年(3.2–4.5),第6–10年3.1次/年(1.7–4.9)。
- 复发VTE累积发生率:2年16%(95%CI 13%–19%),5年25%(21%–29%),10年36%(28%–45%)。
- 第1年每100人年复发率男性11.9次(9.6–14.4)、女性8.9次(6.8–11.3);10年累积发生率男性41%(28%–56%)、女性29%(20%–38%)。
- 与孤立性肺栓塞相比,近端深静脉血栓复发率比1.4(95%CI 1.1–1.7),肺栓塞合并深静脉血栓1.5(1.1–1.9)。
- 远端深静脉血栓停药后第1年每100人年复发率1.9次(95%CI 0.5–4.3);复发VTE致死率4%(2%–6%)。
临床怎么用
- 可依据第1年约10%、2年16%、5年25%、10年36%的复发风险及4%致死率,向首次无诱因VTE患者进行预后咨询。
- 男性、近端DVT或PE合并DVT患者复发风险更高,长期抗凝决策时应纳入考量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To determine the rate of a first recurrent venous thromboembolism (VTE) event after discontinuation of anticoagulant treatment in patients with a first episode of unprovoked VTE, and the cumulative incidence for recurrent VTE up to 10 years. DESIGN: Systematic review and meta-analysis. DATA SOURCES: Medline, Embase, and the Cochrane Central Register of Controlled Trials (from inception to 15 March 2019). STUDY SELECTION: Randomised controlled trials and prospective cohort studies reporting symptomatic recurrent VTE after discontinuation of anticoagulant treatment in patients with a first unprovoked VTE event who had completed at least three months of treatment. DATA EXTRACTION AND SYNTHESIS: Two investigators independently screened studies, extracted data, and appraised risk of bias. Data clarifications were sought from authors of eligible studies. Recurrent VTE events and person years of follow-up after discontinuation of anticoagulant treatment were used to calculate rates for individual studies, and data were pooled using random effects meta-analysis. Sex and site of initial VTE were investigated as potential sources of between study heterogeneity. RESULTS: 18 studies involving 7515 patients were included in the analysis. The pooled rate of recurrent VTE per 100 person years after discontinuation of anticoagulant treatment was 10.3 events (95% confidence interval 8.6 to 12.1) in the first year, 6.3 (5.1 to 7.7) in the second year, 3.8 events/year (95% confidence interval 3.2 to 4.5) in years 3-5, and 3.1 events/year (1.7 to 4.9) in years 6-10. The cumulative incidence for recurrent VTE was 16% (95% confidence interval 13% to 19%) at 2 years, 25% (21% to 29%) at 5 years, and 36% (28% to 45%) at 10 years. The pooled rate of recurrent VTE per 100 person years in the first year was 11.9 events (9.6 to 14.4) for men and 8.9 events (6.8 to 11.3) for women, with a cumulative incidence for recurrent VTE of 41% (28% to 56%) and 29% (20% to 38%), respectively, at 10 years. Compared to patients with isolated pulmonary embolism, the rate of recurrent VTE was higher in patients with proximal deep vein thrombosis (rate ratio 1.4, 95% confidence interval 1.1 to 1.7) and in patients with pulmonary embolism plus deep vein thrombosis (1.5, 1.1 to 1.9). In patients with distal deep vein thrombosis, the pooled rate of recurrent VTE per 100 person years was 1.9 events (95% confidence interval 0.5 to 4.3) in the first year after anticoagulation had stopped. The case fatality rate for recurrent VTE was 4% (95% confidence interval 2% to 6%). CONCLUSIONS: In patients with a first episode of unprovoked VTE who completed at least three months of anticoagulant treatment, the risk of recurrent VTE was 10% in the first year after treatment, 16% at two years, 25% at five years, and 36% at 10 years, with 4% of recurrent VTE events resulting in death. These estimates should inform clinical practice guidelines, enhance confidence in counselling patients of their prognosis, and help guide decision making about long term management of unprovoked VTE. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42017056309.
引用
- Khan F, Rahman A, Carrier M, et al. Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis. BMJ. 2019. PMID: 31340984. doi:10.1136/bmj.l4363
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。